LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Oscar Health 2023 Fourth Quarter and Full Year Earnings Conference Call

January 18, 2024 | Last Trade: US$16.80 0.57 -3.28

NEW YORK / Jan 18, 2024 / Business Wire / Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, will release its fourth quarter and full year 2023 financial results after the market closes on Wednesday, February 7, 2024.

Management will review these results in a conference call beginning at 5:00 PM (ET). The call-in number and webcast link are as follows:

The call will be archived and available on Oscar’s investor relations website (www.ir.hioscar.com) following February 7, 2024 for a period of 90 days.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the health care system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of nearly one million members, as of September 30, 2023. We offer Individual & Family and Small Group plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB